New Triple-Drug attack on liver cancer enters early human testing

This early-phase study tests a new experimental drug (BRII-5395) combined with two approved cancer treatments (sintilimab and bevacizumab) in about 21 adults with advanced liver cancer linked to chronic hepatitis B. The main goal is to check safety and find the right dose, while also looking for signs that the combination shrinks tumors or slows the disease. Participants must have already tried at least one prior cancer therapy.